NEOTEC Program – 25/01/2022

A prestigious initiative by CDTI (Spain) that supports the creation and growth of technology-based companies. It provides funding for business plans that require the development of proprietary technology, focusing on innovation as a core competitive advantage.

Project title: Optimization, validation, and commercialization of CloneSight: a universal test for defining minimal residual disease in cancer patients (SNEO20211112).

Reference: SNEO-20211138

Objective: These objectives are intended to be achieved with the support of Neotec through the development and validation of a unique product that represents a complete market solution for the monitoring of minimal residual disease in at least 70% of cancer patients.

Entities: The optimisation, validation, and commercialisation project for Altum TRACKseq is subsidised by the Centre for the Development of Industrial Technology (CDTI) and supported by the Ministry of Science and Innovation.

Duration: N/A

Money granted: 234.166,10€

Funding entity: CDTI